Cardiac glycosides cause cytotoxicity in human macrophages and ameliorate white adipose tissue homeostasis.

The use of nanomolar concentration of cardiac glycosides could be an attractive therapeutic treatment for metabolic syndrome, characterized by pathogenic infiltration and activation of macrophages.